Immunologic Factor
BioNTech and Regeneron Achieve Positive Phase II Results for mRNA Cancer Vaccine Combo in Melanoma
BioNTech, Regeneron, mRNA cancer vaccine, melanoma, Phase II trial, Libtayo, cemiplimab, BNT111, immunotherapy
China’s Corruption Crackdown Impacts Merck’s Gardasil Sales, Rattling Investors
Merck, Gardasil, China, Corruption Crackdown, Healthcare, Pharmaceuticals, HPV Vaccine
Celldexs anti-cKIT antibody proves it can reduce chronic hives in another phase 2 trial
Antibodies, Trial Phase, Urticaria, chronic hives
BioNTech and Regeneron Achieve Significant Response Rate Success in Phase 2 Trial for mRNA Cancer Immunotherapy BNT111
BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology
BioNTech and Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma
BioNTech, Regeneron, mRNA cancer vaccine, Phase II trial, melanoma, BNT111, cemiplimab, Libtayo
GSK Partners with Flagship Pioneering to Develop 10 Novel Medicines and Vaccines
GSK, Flagship Pioneering, drug discovery, vaccines, respiratory disease, immunology, bioplatform companies, mRNA vaccines, Pfizer, biotech partnership
AstraZeneca’s New Calquence Combinations Show Promise in CLL Treatment: Potential to Shift Clinical Practice
AstraZeneca, Calquence, CLL, Chronic Lymphocytic Leukaemia, BTK Inhibitor, Venetoclax, Obinutuzumab, Clinical Practice, Fixed-Duration Treatment
FDA Approves New Oral Alzheimer’s Therapy, Expands Label for Grifols SCIg Therapy
FDA, Alzheimer’s disease, Grifols, XEMBIFY, immunoglobulin, subcutaneous, immunodeficiency, plasma-derived therapeutics
FDA Raises Concerns Over Potential Overtreatment with AstraZeneca’s Imfinzi for NSCLC
AstraZeneca, Imfinzi, NSCLC, FDA, Overtreatment, Adcomm, Perioperative Treatment, Immune Checkpoint Inhibitors, Neoadjuvant Chemotherapy, Adjuvant Monotherapy
FDA Advisers Call for Revamp of Perioperative Lung Cancer Trials Due to Frustration with AstraZeneca’s Imfinzi Design
FDA, Imfinzi, AstraZeneca, perioperative lung cancer trials, revamp, design issues